We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Morphotek® and Cancer Innovations, Inc. Announce Evaluation and Option Agreement

News   Jul 17, 2009

 
Morphotek® and Cancer Innovations, Inc. Announce Evaluation and Option Agreement
 
 
 

RELATED ARTICLES

Epigenetic Signature May Help People Stay Ahead of IBD

News

In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.

READ MORE

Decoding the Structure of an RNA-Based CRISPR System

News

Over the past several years, CRISPR-Cas9 has moved beyond the lab bench and into the public zeitgeist. Now, scientists from the Salk Institute are reporting for the first time the detailed molecular structure of CRISPR-Cas13d, a promising enzyme for emerging RNA-editing technology.

READ MORE

Ovarian Cancer Biomarker Can Predict Patient Therapy Response

News

Researchers have identified an independent prognostic factor - cancer/testis antigen 45 (CT45) - and have begun to elucidate it's actions. CT45 is associated with extended disease-free survival for women with advanced ovarian cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Genomics Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE